Unicycive Therapeutics (UNCY) had its price target lowered by Benchmark Co. from $21.00 to $15.00. They now have a "speculative buy" rating on the stock.
Unicycive Therapeutics (UNCY) had its price target lowered by Guggenheim from $46.00 to $40.00. They now have a "buy" rating on the stock.
Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]
Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update
Unicycive Therapeutics (UNCY) had its "sell (d-)" rating reaffirmed by
Weiss Ratings.